Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HRH4 | Q9H3N8 | 14/20 | 0.45 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.41 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | MPO | P05164 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4432408 | 0.98 | NPC1 (0.54) | NPC1LMNATP53PKMRAB9A | |
| SCHEMBL5223113 | 0.94 | NPC1 (0.50) | NPC1LMNATP53PKMRAB9A | |
| SCHEMBL574082 | 0.90 | NPC1 (0.45) | NPC1LMNATP53PKMRAB9A | |
| SCHEMBL21847667 | 0.82 | LRRK2 (0.40) | NPC1LMNATP53PKMRAB9A | |
| SCHEMBL29249598 | 0.79 | PSMB8 (0.42) | NPC1LMNATP53PKMRAB9A | |
| SCHEMBL28842193 | 0.79 | PSMB8 (0.42) | NPC1LMNATP53PKMRAB9A | |
| SCHEMBL9386057 | 0.78 | PSMB8 (0.41) | NPC1LMNATP53PKMRAB9A | |
| SCHEMBL3939169 | 0.77 | NPC1 (0.56) | NPC1LMNATP53PKMRAB9A | |
| SCHEMBL26847648 | 0.77 | HRH4 (0.41) | NPC1LMNATP53PKMRAB9A | |
| SCHEMBL24483396 | 0.76 | NPC1 (0.51) | NPC1LMNATP53PKMRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11312722-B2 | Hsp90 inhibitors and uses thereof | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-04-26 | — | — | US | disclosed |
| US-11136311-B2 | Heteroaromatic derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-05 | — | — | US | disclosed |
| US-20200354373-A1 | HSP90 INHIBITORS AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2020-11-12 | — | — | US | disclosed |
| EP-3478675-B1 | HETEROAROMATIC DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-22 | — | — | EP | disclosed |
| EP-0114273-B1 | NEW PHARMACOLOGICALLY ACTIVE PYRAZOLOPYRIDINES | GRUPPO LEPETIT S.p.A. (IT) | 1991-11-06 | — | — | EP | disclosed |
| US-4954508-A | HYPOTENSIVE | GRUPPO LEPETIT S.P.A. (IT) | 1990-09-04 | — | — | US | disclosed |
| EP-0114273-A1 | New pharmacologically active pyrazolopyridines | GRUPPO LEPETIT S.p.A. (IT) | 1984-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200354373-A1 | HSP90 INHIBITORS AND USES THEREOF | HSP90AB1, HSP90B1, HSP90AA1 | NPC1 2456/4885LMNA 4606/4885TP53 763/4885 |
| US-11136311-B2 | Heteroaromatic derivatives as NIK inhibitors | NFKBIA, IKBKG, IKBKE | NPC1 1362/4885LMNA 3126/4885TP53 690/4885 |
| US-11312722-B2 | Hsp90 inhibitors and uses thereof | HSP90AB1, HSP90B1, HSP90AA1 | NPC1 2456/4885LMNA 4606/4885TP53 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.